Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

48.41 +0.57 (+1.19%)
Official Closing Price Updated: 7:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,319,921
Open 48.10
Bid (Size) 48.40 (1)
Ask (Size) 48.47 (14)
Prev. Close 47.84
Today's Range 48.09 - 48.67
52wk Range 39.35 - 63.33
Shares Outstanding 2,222,113,553
Dividend Yield 5.12%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A High-Yield Dividend Stock Worth Considering
BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.18% dividend yield with strong profitability and reasonable valuation, making it a compelling choice for dividend investors. 
Via Chartmill

Performance

YTD
-14.8%
-14.8%
1 Month
+3.3%
+3.3%
3 Month
-23.3%
-23.3%
6 Month
-17.5%
-17.5%
1 Year
+16.7%
+16.7%

More News

Read More
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
Via The Motley Fool
Topics Intellectual Property Retirement
Exposures COVID-19 Intellectual Property Pension
1 Cash-Producing Stock to Own for Decades and 2 to Think Twice About
Via StockStory
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
Via Benzinga
Why BioNTech Stock Soared Today
Via The Motley Fool
Exposures COVID-19
Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug
Via Benzinga
Bristol Myers To Pay Up To $11.1B To BioNTech To Co-Develop, Commercialize Investigational Cancer Drug
Via Stocktwits
Topics Government
Exposures Political
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
From Bristol Myers Squibb
Via Business Wire
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A Potentially Undervalued Dividend Stock
Via Chartmill
1 S&P 500 Stock for Long-Term Investors and 2 to Brush Off
Via StockStory
Topics Stocks
Exposures US Equities
Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
From Bristol Myers Squibb
Via Business Wire
1 Safe-and-Steady Stock to Own for Decades and 2 to Think Twice About
Via StockStory
Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference
From Bristol Myers Squibb
Via Business Wire
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Topics Economy Law Enforcement
Exposures Economy Legal Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Options Corner: Political Turmoil Sets Up A Contrarian Call Spread For Bristol-Myers Squibb
Via Benzinga
Topics Government
Exposures Political
3 Stocks That Will Profit From Trump's Drug Price Cut
Via Benzinga
Topics Government
Exposures Political
Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
From Bristol Myers Squibb
Via Business Wire
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - A High-Yield Dividend Stock Worth Considering
Via Chartmill
What's going on in today's session: S&P500 movers
Via Chartmill
What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks
Via The Motley Fool
Topics Economy Government
Exposures Interest Rates Political
Stay informed with the top movers within the S&P500 index on Wednesday.
Via Chartmill

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 48.41
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 06/06/25 07:00 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 107.57B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 108B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.